BACKGROUND: Necrotising enterocolitis (NEC) is one of the most common and fatal intestinal disorders in preterm infants. Breast-fed infants are at lower risk for NEC than formula-fed infants, but the protective components in human milk have not been identified. In contrast to formula, human milk contains high amounts of complex glycans. OBJECTIVE: To test the hypothesis that human milk oligosaccharides (HMO) contribute to the protection from NEC. METHODS: Since human intervention studies are unfeasible due to limited availability of HMO, a neonatal rat NEC model was used. Pups were orally gavaged with formula without and with HMO and exposed to hypoxia episodes. Ileum sections were scored blindly for signs of NEC. Two-dimensional chromatography was used to determine the most effective HMO, and sequential exoglycosidase digestions and linkage analysis was used to determine its structure. RESULTS: Compared to formula alone, pooled HMO significantly improved 96-hour survival from 73.1% to 95.0% and reduced pathology scores from 1.98 ± 1.11 to 0.44 ± 0.30 (p<0.001). Within the pooled HMO, a specific isomer of disialyllacto-N-tetraose (DSLNT) was identified to be protective. Galacto-oligosaccharides, currently added to formula to mimic some of the effects of HMO, had no effect. CONCLUSION: HMO reduce NEC in neonatal rats and the effects are highly structure specific. If these results translate to NEC in humans, DSLNT could be used to prevent or treat NEC in formula-fed infants, and its concentration in the mother's milk could serve as a biomarker to identify breast-fed infants at risk of developing this disorder.
BACKGROUND:Necrotising enterocolitis (NEC) is one of the most common and fatal intestinal disorders in preterm infants. Breast-fed infants are at lower risk for NEC than formula-fed infants, but the protective components in humanmilk have not been identified. In contrast to formula, humanmilk contains high amounts of complex glycans. OBJECTIVE: To test the hypothesis that humanmilkoligosaccharides (HMO) contribute to the protection from NEC. METHODS: Since human intervention studies are unfeasible due to limited availability of HMO, a neonatal rat NEC model was used. Pups were orally gavaged with formula without and with HMO and exposed to hypoxia episodes. Ileum sections were scored blindly for signs of NEC. Two-dimensional chromatography was used to determine the most effective HMO, and sequential exoglycosidase digestions and linkage analysis was used to determine its structure. RESULTS: Compared to formula alone, pooled HMO significantly improved 96-hour survival from 73.1% to 95.0% and reduced pathology scores from 1.98 ± 1.11 to 0.44 ± 0.30 (p<0.001). Within the pooled HMO, a specific isomer of disialyllacto-N-tetraose (DSLNT) was identified to be protective. Galacto-oligosaccharides, currently added to formula to mimic some of the effects of HMO, had no effect. CONCLUSION: HMO reduce NEC in neonatal rats and the effects are highly structure specific. If these results translate to NEC in humans, DSLNT could be used to prevent or treat NEC in formula-fed infants, and its concentration in the mother's milk could serve as a biomarker to identify breast-fed infants at risk of developing this disorder.
Authors: Jeffrey S Upperman; Douglas Potoka; Anatoly Grishin; David Hackam; Ruben Zamora; Henri R Ford Journal: Semin Pediatr Surg Date: 2005-08 Impact factor: 2.754
Authors: Robert C Holman; Barbara J Stoll; Aaron T Curns; Krista L Yorita; Claudia A Steiner; Lawrence B Schonberger Journal: Paediatr Perinat Epidemiol Date: 2006-11 Impact factor: 3.980
Authors: Anthony R Prudden; Lin Liu; Chantelle J Capicciotti; Margreet A Wolfert; Shuo Wang; Zhongwei Gao; Lu Meng; Kelley W Moremen; Geert-Jan Boons Journal: Proc Natl Acad Sci U S A Date: 2017-06-19 Impact factor: 11.205
Authors: Angela Wahl; Caroline Baker; Rae Ann Spagnuolo; Lisa W Stamper; Genevieve G Fouda; Sallie R Permar; Katie Hinde; Louise Kuhn; Lars Bode; Grace M Aldrovandi; J Victor Garcia Journal: J Virol Date: 2015-08-19 Impact factor: 5.103
Authors: Wyatt E Lanik; Lily Xu; Cliff J Luke; Elise Z Hu; Pranjal Agrawal; Victoria S Liu; Rajesh Kumar; Alexa M Bolock; Congrong Ma; Misty Good Journal: J Vis Exp Date: 2018-02-15 Impact factor: 1.355
Authors: Timothy L Denning; Amina M Bhatia; Andrea F Kane; Ravi M Patel; Patricia W Denning Journal: Semin Perinatol Date: 2016-12-09 Impact factor: 3.300